Roche plans to become TOP 3 obesity players when CT-388 enter the attempt

The Roche holds the AG headquarters on April 11, 2025 in Basel, Switzerland.

Sedat Suna | Getty Images News | Getty pictures

Swiss pharmaceutical company Roche aims at becoming a top thirty -fat -lane player worldwide and presenting a potential rival for heavyweights Novo Nordisk And Eli Lilly While it improves one of his experimental weight loss medication for a study in the late stage.

“I want you to know that I am serious about this goal,” said Teresa Graham, CEO of Roche Pharmaceuticals, on Monday at Roche’s Pharma Day in London in London.

“We know how to break into new markets,” she added.

The pharmaceutical manufacturer said at the beginning of this week that his CT-388 weight loss injection had entered a phase III study, the last phase before a company can obtain official approval-and the latest development in Roch’s emerging but quickly growing pipeline of treatments for obesity and related diseases.

Roche currently has no approved obese medications on the market, but Graham said that the company had set up its treatment suite by 2030.

This includes the closely observed petrelintide drug candidate, which Roche is currently together as part of a partnership with Danish biotech with 5.3 billion US Zealand Pharma.

“I think we are up to date,” said Manu Chakravarthy, Vice President and Global Head of Cardiovascular, kidney and metabolic product development, compared to CNBC about the schedule for petrelintide.

“We are very obliged to pull that [timeline] As much as possible, “he added.

Petrelintide, an emerging form of treatment, known as amylin analogue, adds the existing GLP 1 offer from Roche, including CT-388 and once daily oral CT-996, both of which as part of the first statement from Roche with the purchase of the purchase of 2023 from US-Biotech-Autocarmot-Carmot-Autocotic-Carotic-Automots market were purchased.

Obesity market

The company strengthened its offer last week with a contract for the purchase of USBIOTECH COMPANY 89BIO and with competitors with the development of new treatments for liver diseases to supplement medication for weight reduction.

Graham said investors that she was confident that Roch’s growing suite of drug candidates would help strengthen his chances of success on the increasingly competitive market for weight loss.

Yihan Li, Pharmaanalyst at Barclays, said Roche’s goal of becoming a top three player was “potentially accessible” due to her broad pipeline of obesity assets, but found that the next year would be a “big year” for her test reading.

“It is even more important that the obesity market is currently only a duopol. So it will be a question mark of how big the gap between Roche and Novo/Lly will be,” she wrote in E -Mail comments and added that other treatments of the competitor would probably come onto the market before Roche.

It happens that the rivals Eli Lilly and Novo Nordisk have driven to bring their obesity pills onto the market to expand their offer in the middle of the booming demand for their GLP-1 treatments. Both companies also examine Amylin analogues candidates and other experimental treatments.

The couple already dominates the obesity market, even if the competition from Copycat Compound pharmacies has increased.

Nevertheless, Graham suggested that newer market participants could learn important lessons from the first round of obese treatments. In particular, she said “Medicines of the next generation” should meet with non -covered needs with regard to compatibility, weight maintenance, treatment of comorbidities and lean loss of muscle.

“Our differentiation depends on having this width of options,” she said. “We can completely cover the width of this uncovered need.”

“If you don’t have a portfolio of solutions, it is restrictive,” added Chakravarthy.